This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Suyu Shu, PhD; Gregory E. Plautz, MD; John C. Krauss, MD; Alfred E. Chang, MD

JAMA. 1997;278(22):1972-1981.

Abstract
Malignant tumors express antigens that may stimulate and serve as targets for antitumor immunity. Virally induced tumors usually contain integrated proviral genomes in their cellular genomes and often express viral genome—encoded proteins that may stimulate specific host immune responses. Antigens unique to individual tumors that stimulate specific rejection of transplanted tumors have been demonstrated only in experimental animals. Other tumor antigens that potentially can stimulate immune responses are shared by different tumors. These include products of mutated or rearranged oncogenes or tumor-suppressor genes. Tumors may also overexpress tissue differentiation antigens or embryonic antigens, which also have the potential to be recognized by the immune system. The recent identification of tumor antigens recognized by cytotoxic T cells opens up new possibilities for constructing chemically defined antigens for specific immunotherapy. Treatment of malignant tumors in humans by immunologic approaches, although theoretically attractive, has not yet succeeded on a large scale. Important progress in immunotherapy of cancer is emerging with several different treatment modalities.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Tancrede-Bohin et al.
Arch Dermatol 2004;140:1057-1061.
ABSTRACT | FULL TEXT  

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm et al.
Blood 2003;101:4878-4886.
ABSTRACT | FULL TEXT  

Tumor Immunity within the Central Nervous System Stimulated by Recombinant Listeria monocytogenes Vaccination
Liau et al.
Cancer Res. 2002;62:2287-2293.
ABSTRACT | FULL TEXT  

Tumor-Specific Responses in Lymph Nodes Draining Murine Sarcomas Are Concentrated in Cells Expressing P-Selectin Binding Sites
Tanigawa et al.
J. Immunol. 2001;167:3089-3098.
ABSTRACT | FULL TEXT  

Predominant Th2/Tc2 Polarity of Tumor-Infiltrating Lymphocytes in Human Cervical Cancer
Sheu et al.
J. Immunol. 2001;167:2972-2978.
ABSTRACT | FULL TEXT  

A Novel Role of Metalloproteinase in Cancer-mediated Immunosuppression
Sheu et al.
Cancer Res. 2001;61:237-242.
ABSTRACT | FULL TEXT  

In Vitro and In Vivo Induction of a Th Cell Response Toward Peptides of the Melanoma-Associated Glycoprotein 100 Protein Selected by the TEPITOPE Program
Cochlovius et al.
J. Immunol. 2000;165:4731-4741.
ABSTRACT | FULL TEXT  

Photodynamic Therapy-mediated Immune Response against Subcutaneous Mouse Tumors
Korbelik and Dougherty
Cancer Res. 1999;59:1941-1946.
ABSTRACT | FULL TEXT